Cover Image

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Darrick K. Li, Yuan Pu, Yihang Liu, Kisung You, Michael G. Nanna, Alyssa Harris, Joseph J. Y. Sung, Loren Laine, Dennis L. Shung
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Systematic review: The use of large language models as medical chatbots in digestive diseases
by: Mauro Giuffrè, et al.
Published: (2024)

Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban or the combination: Secondary analysis of the COMPASS randomised controlled trial
by: Kanika Sehgal, et al.
Published: (2024)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
by: Jiaqi Shen, et al.
Published: (2026)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
by: Xiaoqing Yang, et al.
Published: (2026)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
by: Lauren Holtslander, et al.
Published: (2025)

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
by: Min Joo Yoon, et al.
Published: (2026)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
by: Jurij Maurer, et al.
Published: (2026)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial
by: Yu Yang, et al.
Published: (2024)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
by: Nauzer Forbes, et al.
Published: (2024)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
by: Silvia Nardelli, et al.
Published: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
by: Yi Xiang, et al.
Published: (2025)

Editorial: Gastrointestinal symptoms—A world of differences
by: Kevin W. Olden
Published: (2024)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
by: Kanghee Park, et al.
Published: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
by: Hassan Javed, et al.
Published: (2025)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs
by: Ali S. Taha
Published: (2026)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
by: Na Tian, et al.
Published: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula
by: Alyssa M. Parian, et al.
Published: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
by: Jonggi Choi
Published: (2025)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
by: Min Joo Yoon, et al.
Published: (2026)

Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
by: Hannes Hagström, et al.
Published: (2025)

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract
by: Michael Camilleri, et al.
Published: (2025)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
by: Benjamin Douglas Liu, et al.
Published: (2025)

Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
by: Nobuharu Tamaki, et al.
Published: (2025)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
by: Julia Karady, et al.
Published: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
by: Sung Won Chung, et al.
Published: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index in predicting mortality and guiding prehabilitation
by: Sara J. Harris, et al.
Published: (2024)

Letter on ‘Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis ( EndoFOD )—A Randomised, Controlled Crossover Feeding Study’
by: Wancheng Zhao, et al.
Published: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
by: C. C. Mark Cheah, et al.
Published: (2025)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
by: Mo‐Yao Tan, et al.
Published: (2024)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
by: Xiao‐Dong Zhou, et al.
Published: (2025)

Letter: Identifying the Best Model for Predicting Post‐SVR HCC
by: Hidenori Toyoda
Published: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
by: Qiang Hu, et al.
Published: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
by: Jessica D. Lee, et al.
Published: (2025)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS
by: Cecilia Katzenstein, et al.
Published: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
by: Yewan Park, et al.
Published: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
by: You‐Jian Xu, et al.
Published: (2024)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
by: Anthony O'Connor, et al.
Published: (2024)

Letter: Post‐endoscopic management after upper gastrointestinal bleeding—Replenishment of iron loss
by: Palle Bager, et al.
Published: (2024)